Ali Bazarbachi, MD, PhD is a Professor of Medicine (Hematology and Oncology), Professor of Anatomy, Cell Biology and Physiological Sciences, Associate Dean for basic research, and Director of the bone marrow transplantation program at the American University of Beirut-Medical Center. He received his MD and PhD degrees, residency and fellowship training at the University of Paris VII in France. Dr. Ali Bazarbachi’s basic and translational research focuses on targeted therapies for leukemia and lymphoma as well as post-transplant pharmacological interventions. He has co-authored more than 340 articles in leading scientific journals including The New England Journal of Medicine, Science, Journal of Experimental Medicine, The Lancet Oncology, Journal of Clinical Oncology, Blood, Nature Communication, and Cancer Research. He is the Chairman of the EMBMT Leukemia Working Party, Chairman of the NCCN Lymphoma Group for Middle East and North Africa, past President of the Lebanese Society of Hematology, and Associate Editor of Bone Marrow Transplantation. He garnered multiple prestigious national and international awards including the 2008 award of the French National Academy of Medicine.
Dr Eileen M Boyle is a physician-scientist currently acting as postdoctoral fellow at NYU Langone’s Myeloma Research Program.
After completing her hematology training in Lille University, France, she served as an instructor in Lille University Hospital under the supervision of Prof Thierry Facon. During her training she served as clinical Research Fellow at the Royal Marsden and ICR, London UK, and she obtained her MSc in human genetics 2014. She continued her research in myeloma genetics at the University of Arkansas for Medical Science (UAMS, AR, USA) and Lyon University (Lyon, France) under the supervision of Prof Brian Walker and was awarded a PhD in Molecular genetics in 2020 before starting a postdoc at NYU Grossman’s school of medicine in Prof Gareth Morgan’s laboratory.
Her clinical activity has focused on the management of plasma cell disorders including precursor conditions, and light-chain amyloidosis in both the Lille University Hospital, France and the Royal Marsden, London, United-Kingdom. In addition to her clinical activities, she has dedicated several years to the study of the genetics of plasma cell disorders with a particular focus on the mechanisms of disease progression and high-risk disease.
She has co-authored several papers and acts as a reviewer for multiple journals and funding organizations.
Eolia Brissot, MD, PhD, is Associate- Professor of Hematology and works at Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). She attended the University of Nantes, France, where she completed her medical degree. She then undertook a PhD at Sorbonne University in Paris, France, before working at the laboratory of hematologic stem cell transplantation unit at the National Institute of Health, Bethesda, USA. She is secretary of the ALWP of the European Society for Blood and Marrow Transplantation (EBMT). She has a special clinical and research focus on the development of GVHD prophylaxis, immunotherapy and different aspects of therapy of acute lymphoblastic leukemia.
Nelson Chao, MD, MBA Professor of Medicine, Immunology and Pathology Duke University
Dr. Chao is Professor of Medicine and Immunology and the Chief of the Division of Cellular Therapy/BMT and the Division of Hematologic Malignancies at Duke University. He received his undergraduate degree from Harvard University, MD from Yale University and did his post-graduate training at Stanford University. He then joined the faculty at Stanford University. He was the Associate Director of Stem Cell Transplantation at Stanford University prior to moving to Duke University in 1996 as the Program Director of the Bone Marrow Transplantation Program. The program became a Division within the Department of Medicine in 2000 and was renamed as the Division of Cellular Therapy/BMT. It became the Hematologic Malignancies and Cellular Therapy Division in 2012. He was also named the Director of Global Oncology in the Duke Global Health Institute in 2013. He is also the Co-Director of the Clinical Stem Cell Transplantation Laboratory and continues to direct his own research laboratory focused on hematopoiesis, understanding and preventing graft-versus-host disease and improving immune reconstitution. He obtained his MBA from the Fuqua School of Business at Duke University in 2000. He is the author of over 300 peer-reviewed papers. He active nationally and internationally in the area of stem cell transplantation and in nuclear biodefense. He is also a co-founder of Aldagen, and C2 Regenerate, start up biotechnology companies in Research Triangle Park.
Dr. Dholaria is currently an assistant professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies, and stem cell transplantation. He has conducted studies investigating the outcomes of non- Hodgkin lymphoma patients undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team’s work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to mitigate cytokine release syndrome and neurotoxicity associated with CAR T-cell therapy.
Dr. Brian Engelhardt is an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, and a Staff Physician at the Veterans Affairs Tennessee Valley Healthcare System. Dr. Engelhardt’s laboratory focuses on investigating immune-mediated complications following allogeneic hematopoietic cell transplantation including post-transplant diabetes mellitus (PTDM). By studying the physiology and immunology of new-onset diabetes after hematopoietic cell transplant, Dr. Engelhardt performs mechanistic studies that uncover new connections between metabolic complications and immune regulation while simultaneously identifying novel targets for intervention. The goal of this research is to decrease the morbidity and mortality associated with hyperglycemia after transplant. Dr. Engelhardt has presented his work at various international scientific conferences including: the American Society of Hematology Annual Meeting, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, the American Society of Clinical Oncology Annual Meeting, and the Japanese Society for Transplantation and Cellular Therapy Annual Meeting, as well as others. Dr. Engelhardt’s research receives support from the National Institutes of Health/National Heart, Lung, and Blood Institute.
Emeritus Professor of Hematology, ‘Sapienza’ University of Rome. He earned his medical degree in Turin, Italy, and specialized in pediatrics and hematology. Worked at the MRC Leukaemia Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London between 1976 and 1979. Sabbatical at Memorial Sloan-Kettering Cancer Center, New York, between 1991 and 1992.
He is part of the European LeukemiaNet (ELN) Steering Committee and referee for national and international funding agencies. Chairman of the Scientific Committee of the 4th EHA Congress, Barcelona 1999, councilor of EHA until December 2002, and member of the Education Committee of EHA until December 2005. President-Elect, President and Past-President of EHA during the years 2007-2013. Chairman Education Committee and Outreach Unit of EHA up to June 2017. Member of EHA’s Global Outreach Committee.
Has authored over 800 papers, reviews and books. Has been co-editor of Leukemia and Lymphoma, and associate editor of the British Journal of Hematology and of The Hematology Journal. Editor-in-chief of The Hematology Journal up to December 2004 and of Haematologica from January 2005 to February 2008.
Prof. Sebastian Giebel is an internal medicine, hematology and clinical transplantation specialist. He is head of the Department of Bone Marrow Transplantation and Onco-Hematology and Deputy Director for Clinical Matters in Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice, Poland. Prof. Giebel is the President of the Polish Adult Leukemia Group (PALG) and the Polish Lymphoma Research Group (PLRG), the Secretary of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), board member of The Polish Society of Hematology and Transfusion Medicine, member of the European Working Group for Adult Acute Lymphoblastic Leukemia. An author of over 250 scientific papers, mainly in the field of hematology and hematopoietic cell transplantation. In 2017 he was awarded Jedrzej Sniadecki Medal of the Polish Academy of Sciences, the highest national distinction in the field of medicine.
Christian GISSELBRECHT Professor of Hematology
Hôpital Saint Louis
Christian Gisselbrecht, MD is emeritus professor of hematology at Paris University at the Hôpital Saint Louis in Paris. He is co-founder of the GELA, now LYSA ( Lymphoma Study Association) in 1987 and president of the group until 2002.
Dr Gisselbrecht has been lead investigator of several clinico-pathologic studies, and stem cell transplantation with a focus on relapses or poor prognosis diffuse large B cell with the CORAL study, standard of care before CAR T . He is an expert of the European Medecine Agency. He has published over 300 peer-reviewed papers and several book chapters.
Christopher Hourigan received both his medical degree and D. Phil. in Human Immunology from Oxford University. After residency training in medicine at Guy’s and St. Thomas’ Hospital in London and the Johns Hopkins Bayview Medical Center in Baltimore, he joined the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital where he was both a clinical fellow in medical oncology and a postdoctoral research fellow in the Immunology and Immunotherapy research program. He is ABIM board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Hourigan came to the NHLBI in 2012. After almost three years as an Assistant Clinical Investigator, Dr Hourigan was appointed as an Investigator in March 2015. Dr. Hourigan is a Fellow of the Royal College of Physicians, and the recipient of the NHLBI Directors Award, the NHLBI Orloff Award, the NIH Bench to Bedside Award, the NIH Directors Challenge Innovation Award, an American College of Physicians Early Career Physician Award, the American Society for Clinical Investigation (ASCI) Young Physician-Scientist Award and the Presidential Early Career Award for Scientists and Engineers (PECASE).
Dr. Hourigan’s research focuses on three complementary approaches that are united by an overriding theme of performing translational research in order to find ways to detect, prevent and treat AML relapse. These efforts are strengthened by collaborations with a variety of clinical colleagues from leukemia and transplant centers from around the world.
Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia. Over the past 5 years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others. These include: 1) the Hyper CVAD-ofatumumab regimen in ALL; 2) clofarabine in myeloid malignancies; 3) hypomethylating agents in AML and MDS; 4) Tyrosine kinase therapy in CML; and 5) triple therapy in AML. This research has also provided insight into the biology of leukemias. He has extensively addressed the question of resistance to tyrosine kinase inhibitors and to analyze the outcome of these patients. We have identified different mechanisms of resistance and described the clinical significance of them. This has clinical significance in establishing new milestones and leading to personalized therapy. This has tremendous consequences at the scientific and financial levels. He was also actively associated with frontline studies of nilotinib and dasatinib which resulted in FDA approval of these agents for frontline CML therapy in 2010. In addition we have recently addressed the question of genomic instabilities in patients with low-risk MDS who may need earlier therapeutic intervention. This served as a rationale for the first study in the world randomizing such patients to either 5-azacitidine or decitabine. Identifying patients at risk and applying earlier intervention may significantly improve their prognosis. He is leading our efforts to test triple therapy in AML (nucleoside analogs + anthracyclines + cytarabine). The interim results from this randomized trial show a significant improvement in outcome in patients who receive the nucleoside analog clofarabine. This may change the standard of care for the management of patients with AML. Furthermore, I am currently investigating the benefit of adding humanized monoclonal antibody for the treatment of patients with ALL (ofatumumab and HCVAD) and collaborating in the development of monoclonal antibody studies in adult ALL. Finally, he has authored or co-authored hundreds of peer reviewed medical publications and have served on editorial boards of several scientific journals.
I am a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins and my academic focus is cellular therapy and transplantation in the treatment of high-risk hematological malignancies especially myeloproliferative neoplasms. My primary research focus is to develop strategies to improve outcomes and prevent relapse of hematological malignancies following allogeneic stem cell transplantation. I also serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients.
Dr. Tapan Kadia is Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. In addition to being the associate program director of the leukemia fellowship program, he is actively involved in clinical and translational research for the treatment of patients with leukemia. His particular focus is in developmental therapeutics in acute leukemia, including individualized frontline therapy, biologically rational targeted therapy, and longer term maintenance strategies in AML and ALL. He is primary investigator on numerous trials in acute myeloid leukemia, T-cell leukemias, bone marrow failure states, and is a leader in these. He has received numerous academic and clinical honors and awards for his studies and clinical research. Additionally, he’s authored over 350 peer-reviewed articles, numerous abstracts, and has been invited to speak nationally and internationally about his work.
His childhood and medical school years in Nigeria exposed him to the devastating effects of sickle cell disease (SCD) in affected individuals and their families, were >150,000 are born annually with the disease. SCD affects about 100,000 people in the United States, mostly African Americans, but our healthcare systems struggle to deliver effective care. He established the Vanderbilt Adult Sickle Cell Disease Clinic shortly on his arrival at Vanderbilt in August 2001. From interrogating the brain in SCD, exploring innovative novel pain regimens that reduce the need for daily high-dose opioids, using the chronic care model of care, incorporating novel disease modifying therapies, to the use of haploidentical stem cell transplants as a curative modality, he is spearheading ways to improve care and help more patients lead happy, productive lives. Dr. Kassim has treated patient care not merely as a profession, but as a humanitarian and global health mission. He frequently travels to West Africa (Ghana and Nigeria) to advance the care of children and adults with SCD in low resource setting. He is a member of the American Society of Hematology Committee on Promoting Diversity, a member of the Bone Marrow Transplant Clinical Trials Network, Special Populations Committee that highlights needs of under-represented minorities and a member of the Steering Committee for the ASBMT Survivorship Group, with focus on minority populations.
Prof . Dr. A.P. Kater’s fundamental, translational and clinical research as a clinical hematologist is focused on chronic lymphocytic leukemia (CLL).
From 2008 to 2009 he also worked as a postdoc at the Moores Cancer Center and the Laboratory of Gene Regulation and Signal Transduction at the University of California (San Diego, US). Within the Amsterdam University Medical Center (a merger of the AMC and the Vumc), he is deputy head of the Dept. of Hematology and chairman of the clinical research committee.
Kater has been awarded with grants for his research. In 2019 he received an ERC Consolidator grant in order to perform studies on the interactions between CLL cells and the adaptive immune system. He also received grants from the Dutch Cancer foundation, European Union consortia, pharma-industry and various research supporting foundations.
Since September 2014, he has been chair of the Dutch CLL working group at the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON), in 2021 he is president-elect of the HOVON executive board. He is the current chairman of the EHA Scientific Working Group on CLL (ERIC). In 2021 he became member of the scientific board of the European School of Haematology. He is on the editor board of the journals Blood and Haematologica.
Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Professor of Medicine
Director, Blood and Marrow Transplantation and Cellular Therapies
Medical Director, Cancer Research Office (Florida Campus)
Director, Inpatient Hematology Unit
Mayo Clinic Florida
Dr. Kharfan-Dabaja is a Professor of Medicine, Vice-Chair of Hematology, and the Director of the Blood and Marrow Transplantation and Cellular Immune Therapies programs at Mayo Clinic in Jacksonville, FL. His main interests are chimeric antigen receptor T-cell (CAR-T) therapy for lymphoid neoplasms and reduced intensity allogeneic hematopoietic cell transplantation for various hematologic malignancies.
He is Board certified in Medical Oncology and Hematology. He is a co-Chair of the Lymphoma Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), the chair of the Payer Relation Committee and a member of the Clinical Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy, and a member of the Committee on Investment and Audit of the American Society of Hematology.
He has published over 330 peer-reviewed manuscripts, 21 book chapters and has presented his work at various regional, national and international scientific platforms.
Per Ljungman is emeritus professor in hematology, Karolinska Institutet and senior physician in the Dept. of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden. His main research interests have been viral infections most recently COVID-19 and vaccinations in severely immunocompromised in particular allogeneic stem cell transplant recipients on which topics he has published extensively (> 400 peer reviewed papers). He is honorary member of the European Society for Blood and Marrow Transplantation and the Swedish Society for Hematology.
Giovanni Martinelli is the Scientific Director of Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, IRST- IRCCS, Italy since 2018.
From 1993 to 2001 he has been Medical doctor – Hematology Unit- at University of Bologna Institute of Hematology “L. E A. Seràgnoli”, Italy and from 2001 -2017 he has been Professor at Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Italy.
He is Medical Doctor (1985), with a post-doctoral degrees in Hematology (1988) and Medical Genetics (1992).
His main research and clinical activity involve the area of acute and chronic myeloid leukemia and myelodisplastic syndromes.
His major areas of expertise and interest are: Conduction of several Phase I-II-III clinical trials and biological research projects on AML, LAL, MDS and CML as Principal Investigator. His Research and clinical activities are devoted to translational studies mainly on acute leukemia focusing on the molecular characterization of acute leukemia primary samples using NGS and SNP arrays technologies. Different translational project are currently integrating genomics data with functional analyses in order to identify novel genetic alterations and to evaluate them as potential targets for innovative therapies.
He has the skills, expertise and authority to lead a team and he has the capacity of using the resources in a flexible way to achieve the project objectives.
Achievements: He has been involved in different National and International project some of these are following:
-Responsible of the individual program – “Diagnosis and treatment of acute leukemias and myelodysplastic syndromes” Sant’ Orsola Hospital, Bologna.
-FP7-HEALTH-2012-INNOVATION-1 Seventh framework programme 2011 Principal Investigator of financed International project: “Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia – NGS- PTL”.
-Winner of 2016 Investigator Grant, AIRC, Associazione Italiana per la Ricerca sul Cancro
-Coordinator (2017) of WP5 of the IMI2 Call topic identifier H2020-JTI-IMI2-2015-06- two-stage project named Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms In HematologY (HARMONY)
-Partner and WP4 coordinator of the ERA-PER MED call 2018 project: Synthetic Lethality for Personalized Therapy-based Stratification In Acute Leukemia
-WP LEADER (2019) of H2020 project ONCORELIEF
-WP LEADER (2020) of Erapermed Project SYNTHERAPY
He published more than 500 papers in national and international journals and his H-Index from Scopus (2019) is 87.
Profilo italiano in breve:
Giovanni Martinelli – da gennaio 2018 Direttore Scientifico dell’Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS di Meldola (FC) – prima medico dirigente all’AO Bologna, Policlinico S. Orsola – Istituto di Ematologia “Seragnoli”, professore associato in Malattie del sangue presso la Facoltà di Medicina e Chirurgia dell’Università di Bologna e docente alla Scuola di specializzazione in Ematologia, ove era Responsabile Coordinatore del Laboratorio di Biologia Molecolare “Candida Fiorini” dell’Istituto di Ematologia “Seràgnoli” – è tra i migliori ricercatori italiani con oltre 500 pubblicazioni su riviste nazionali ed internazionali, con H-index di 87 (Scopus 2019). Membro di società scientifiche e gruppi di lavoro nazionali ed internazionali, è “editor in chief” e revisore di numerose riviste (tra cui Hematology reports, Leukemia, Lancet). Martinelli è inoltre Principal Investigator di più di 50 protocolli clinici di cui la maggior parte di ideazione originale e non company sponsored. Collaboratore di Reti e Gruppi di ricerca nazionali ed internazionali, è organizzatore di congressi e docente in corsi e scuole di specializzazione universitaria. Durante l’attività assistenziale si occupa primariamente di pazienti con linfoma, mieloma multiplo, leucemia acuta.
IRST è polo d’eccellenza a livello nazionale e internazionale interamente dedicato alla cura, alla ricerca clinica, sanitaria, biologica e traslazionale e alla formazione in campo oncologico. Operativo dal 2007 all’interno delle strutture dell’ex Ospedale Civile di Meldola, IRST, quale centro dall’alto potenziale tecnologico e scientifico, dialoga con le più qualificate strutture nazionali e internazionali di cura e studio delle patologie neoplastiche, proponendosi quale soggetto ideale per condurre ricerca ad alto livello. I progetti di ricerca sono ideati in sinergia con la Struttura Complessa di Biostatistica e Sperimentazioni Cliniche che coadiuva i ricercatori nel programmare e coordinare studi in ambito oncologico scientificamente rilevanti, nel rispetto delle normative esistenti e dei requisiti etici, garantendo i requisiti della ricerca e la trasferibilità nella pratica clinica.
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM) since 2020.
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator of several international randomized phase 3 clinical trials evaluating Carfizomib, Ixazomib, Venetoclax, Daratumumab or Isatuximab. He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
His research is widely published. Professor Moreau has authored or coauthored more than 400 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.
After completing my Internal Medicine training at Johns Hopkins, in the Osler Medical Program, I subsequently completed both hematology and oncology training at MD Anderson Cancer Center (MDACC). I was selected as a chief fellow in my second year of training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia. I have an active clinical schedule during which I see patients: 2 full days of clinic per week, and 2 months of inpatient service per year. I have fellow teaching responsibilities as a Leukemia hematology/oncology Course Director and was the sole recipient of the MDACC Gerald P Bodey Award for Excellence in Education in 2020. My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare myeloid malignancies, including for adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML).
Valeria Santini is Associate Professor of Hematology at the University of Florence, Italy. She runs the MDS Unit- Hematology- Department of Experimental and Clinical Medicine- AOU Careggi, University of Florence. Her interests are focused on clinical and translational research in MDS and elderly AML. Professor Santini is President of the Scientific Committee of Fondazione Italiana per lo studio delle sindromi mielodisplastiche (FISiM) and Italian Network of MDS Registries. She belongs to ASH, EHA SOHO and MDS Foundation. She is also an author of more than 200 peer-reviewed papers published in international journals, she has been member of the Editorial board of Blood journal, and documented reviewer for high impact factor scientific journals. She has been an invited speaker at numerous international meetings including the American Society of Clinical Oncology (ASCO 2007: educational session on MDS), American Society of Hematology (ASH 2012, ASH 2016: educational sessions on MDS), European Haematology Association (EHA 2016, EHA 2020, EHA 2022: Educational sessions on MDS) and national haematology societies of several countries.
Dr Savani’s area of specialization is in the treatment of hematological malignancies, stem cell transplantation/ cellular therapy, and his primary field of research is in the long-term follow-up after transplantation/ cellular therapy, including regimen-related toxicity/ supportive care, and outcomes analysis of hematological malignancies, transplant and cellular therapy recipients. Dr Savani has published over 500 peer-reviewed articles, reviews, book chapters, editorials, perspectives and commentaries in the field of hematological malignancies, stem cell transplantation and cellular therapy. He is Co-Editor-in-Chief of journals Bone Marrow Transplantation (EBMT journal) and Clinical Hematology International (IACH journal) and also serves as an editorial advisory board member for several journals in the field. Dr Savani is currently leader of the Conditioning Regimen Subcommittee of the Acute Leukemia Working Party of the EBMT. He also serves as Co-Chair Regimen-Related Toxicity and Supportive Care-CIBMTR and medical monitor for Blood and Marrow Transplant Clinical Trial Network (BMT-CTN). Dr Savani is a member of the ASH Committee on Practice (COP) and a liaison member from the COP to the ASH Task Force on Immunotherapies subcommittee. He has recently edited several special issues for Seminars in Hematology, Hematology/ Oncology Clinics of North America and edited Wiley books entitled “Blood and Marrow Transplantation Long Term Management: Prevention and Complications” (first ed 2014, second ed May 2021) and “Clinical guide to transplantation in lymphomas” (first ed 2015). Co-authored handbook on Leukemia (FAST FACTS: Leukemia, first ed 2019). He has served as a Foundation for the Accreditation of Cellular Therapy (FACT) adults program clinical/ marrow collection facilities and Immune Effector Cell (IEC) inspector role since 2011.
Phillip Scheinberg, MD Hospital A Beneficência Portuguesa, São Paulo, Brazil
Dr Phillip Scheinberg graduated in Medicine from the University of Santo Amaro, São Paulo, Brazil in 1995. He then undertook residencies in Internal Medicine at the University of São Paulo (1996–1997) and at Mount Sinai Medical Center, Florida, USA (1997–2000). From 2000 to 2001, he worked as Medical Chief Resident at Mount Sinai Medical Center.
Dr Scheinberg undertook his hematology-oncology fellowship and training at the Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health from 2001 to 2006. He then remained on staff at the Hematology Branch of the NHLBI from 2006 to 2011, where he developed several clinical protocols in bone marrow failure syndromes as well as conducted laboratory research in bone marrow failure syndromes, bone marrow transplantation, cellular immunity against viral, tumoral and allogeneic antigens. He is currently Head of the Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil.
Being educated at the medical schools of Würzburg, Salamanca, Basel and New York University, Dr. Schmid graduated from University Medical School in Würzburg (Germany) in 1996 and then received basic training in internal medicine at the Medizinische Poliklinik of the Ludwig-Maximilian-University in Munich. In 1998, he joined the group of Hans Kolb at the José Carreras Unit for hematopoietic transplantation in Munich. There, experimental and clinical studies on adoptive immunotherapy, as well as transplant strategies in high-risk leukemia were among his main areas of research. Since 2005 he is the leader of the immunotherapy subcommittee of the EBMT Acute Leukemia Working Party. In 2005, he became head of the stem cell transplant unit at the university hospital of Augsburg, Germany. In 2022 he became full professor at the medical faculty at Augsburg University, where he is also member of the research commission and leads the local clinical trial office including early clinical trial unit.
Dr Sierra graduated with honours in medicine and surgery in 1979 and from 1980 to 1995 trained in hematology, completing his PhD and was a staff member at the Hospital Clínic of Barcelona (Profs. Ciril Rozman, Emili Montserrat, Albert Grañena). In 1995 and 1996, he was a postdoctoral translational scientist at the Fred Hutchinson Cancer Research Center, were he worked with Profs. Anasetti, Hansen, Martin, Storb and Appelbaum. In 1997 Dr. Sierra returned to Barcelona as Director of Hematology at the University Hospital de la Santa Creu I Sant Pau. He became Vice-Dean of the Faculty of Medicine and full professor of Medicine in of the Autonomous University of Barcelona in 2006. In 2013, Dr. Sierra made another stay in the US, this time at the Moffitt Cancer Center in Tampa, Florida. His research interests include the clinical impact of molecular alterations in acute myeloid leukemia and the innovative modalities of AML therapy and hematopoietic transplantation. Dr. Sierra has published more than 450 peer-reviewed articles in journals such as the New England Journal of Medicine, JAMA, Lancet, Nature Reviews in Clinical Oncology, Journal of Clinical Oncology, Blood, Leukemia, and Haematologica, among others. He has been co-author of the European LeukemiaNet guidelines on Acute Myeloid Leukemia in the editions of 2010, 2017 and 2022. Jorge Sierra served as President of the Spanish Society of Hematology, the Catalan Society of Hematology and was member of the Executive Board of the European Haematology Association. In 2017 he became full member of the Royal Academy of Medicine of Catalonia.
Catherine J. Wu, MD is a Professor of Medicine and Chief, Division of Stem Cell Transplantation and Cellular Therapies at the Dana-Farber Cancer Institute, Boston. She is a member of the National Academy of Medicine and the Association of American Physicians. She received her M.D. from Stanford University School of Medicine and completed her clinical training in Internal Medicine and Hematology-Oncology at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, MA, and joined the staff at the Dana-Farber Cancer Institute in 2000. At DFCI, she has initiated an integrated program of research and clinical activities that centers on dissecting the basis of effective anti-tumor immunity, and particular focus on the use of genomics-based approaches to discover immunogenic antigen targets and to understand the molecular basis of therapeutic response and resistance.
Amer Zeidan, MBBS, MHS is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies DART (Disease Aligned Research Team), and the director of CME at Hematology division at Yale Cancer Center. Dr. Zeidan has completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML). The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers diseases and their therapies.
We are LIVE NOW!
✍️Join us for FREE https://us06web.zoom.us/webinar/register/WN_RJmJA_rRTr6-Qigkd83vMw
@TheIACH Journal Club👉
Addition of isatuximab to lenalidomide bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with MM
@Mohty_EBMT @BrunoPaiva_UNAV @EliasKarlMai
Join TODAY'S Journal Club👉
Addition of isatuximab to lenalidomide bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with MM
Dec 6 7pm CET
@Mohty_EBMT @BrunoPaiva_UNAV @EliasKarlMai
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.